Worthington & Caron, PC to Sponsor 7th International Mesothelioma Symposium
Worthington & Caron, PC is proud to be lead sponsor of the The 7th International Mesothelioma Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma where international experts will meet to discuss the latest treatment options for mesothelioma.
The 7th International Symposium will be held Saturday, September 30th at the UCLA Meyer & Renee Luskin Conference Center in Los Angeles, California.
Course Chair Dr. Robert Cameron has over 30 years of experience treating patients with malignant pleural mesothelioma. He has played a vital role in the development of lung-sparing treatments including the pleurectomy/decortication surgery and a number of adjuvant therapies. Dr. Cameron serves as Director of the Comprehensive Mesothelioma Programs at UCLA Medical Center and the West Los Angeles VA Medical Center. He also serves as Scientific Advisor at the Pacific Mesothelioma Center.
Dr. Cameron will be joined by leading mesothelioma experts who will highlight recent advancements in mesothelioma treatment and cutting-edge research.
All physicians and nurses attending will receive continuing medical education (CME) course credit.
*Patients and families are welcome and encouraged to attend.
For more information, and to register, click here.
Presentations and Discussions:
- Immune Checkpoint Blockade in Malignant Mesothelioma:
- Luana Calabrò, MD, Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy.
- The Potato in the Tailpipe! Disabling Mitochondrial Peroxide Metabolism As An Effective Therapeutic Approach for MPM:
- Brian Cunniff, PhD., Faculty Scientist, Department of Pathology, Vermont Cancer Center, University of Vermont College of Medicine.
- Trans Arterial Chemo Perfusion:
- Jacques P. Fontaine M.D, Thoracic Surgeon, Associate Professor, University of South Florida, Moffitt Cancer Center.
- Combining Angiogenesis Inhibition with Chemotherapy, Who, How and What's Next?:
- Anna Nowak, MBBS, FRACP, PhD., Professor, Faculty of Medicine, University of Western Australia.
- Inflammasome Modulation by Chemotherapeutics in Mesothelioma: Is This a New Possibility?:
- Arti Shukla, PhD, Associate Professor, Departments of Pathology and Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont.
- Targeting the Epigenome in Malignant Pleural Mesothelioma:
- David S. Schrump, MD, MBA, FACS, Senior Investigator and Surgical Chief CCR/NCI, Bethesda, MD.
- Recent Findings on Mesothelioma and BAP1:
- Haining Yang, MD, PhD., Professor, Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
- Surgery for Mesothelioma: Is There a Future?:
- Robert B. Cameron, MD, FACS
- Intracavitary Therapeutics for Pleural Malignancies:
- Olga Olevsky, MD
- Engineering Mesenchymal Stem Cells for Immunotherapy of Mesothelioma:
- Robert B. Cameron, MD, FACS
- The Benefits of a Mesothelioma Caregivers Support Group:
- Lien Hua-Feng, RN, MSN, NP-C
- Resources for Research-Student Internship Program:
- Clare Cameron, BA
Related Posts: